Literature DB >> 9521229

Complication-free duration and the risk of development of retinopathy in elderly diabetic patients.

O Cohen1, K Norymberg, E Neumann, H Dekel.   

Abstract

BACKGROUND: Determining which diabetic patients are at risk for complications and targeting these patients for intensive therapy may avoid the unwanted consequences of hypoglycemia in low-risk patients. Since aging is associated with a decrease in the incidence of diabetic retinopathy, we assessed whether long complication-free duration can define elderly patients at lower risk for future development of diabetic retinopathy.
METHODS: In a 10-year clinic-based study, we studied 833 type 2 diabetic patients who were free of diabetic retinopathy and older than 50 years, followed up for more than 4 years. Data included demographic and clinical information on arrival, updated every 3 to 6 months, and yearly direct ophthalmoscopic examination after pupillary dilation by experienced ophthalmologists. All the data were prospectively compiled on relational databases. End points studied were presence of retinopathy, nephropathy, peripheral neuropathy, peripheral vascular disease, hyperlipidemia, and hypertension.
RESULTS: Of the patients without retinopathy at the age of 50 years, 10% developed retinopathy during 4 years of follow-up. These patients had longer duration and younger onset of diabetes than the group without retinopathy at the 4-year follow-up. Clustering of microvascular and macrovascular complications was noted. Discriminant analysis showed the following factors to be significant and independent predictors of the development of retinopathy in the elderly: duration of diabetes, body mass index, age, and glucose control.
CONCLUSIONS: A long complication-free period does not define elderly patients with type 2 diabetes who are at lower risk for future development of retinopathy. On the contrary, the increase in disease duration is significantly associated with the development of retinopathy in this age group, as described in younger patients.

Entities:  

Mesh:

Year:  1998        PMID: 9521229     DOI: 10.1001/archinte.158.6.641

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  7 in total

1.  Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: rationale and design.

Authors:  Steven Shea; Justin Starren; Ruth S Weinstock; Paul E Knudson; Jeanne Teresi; Douglas Holmes; Walter Palmas; Lesley Field; Robin Goland; Catherine Tuck; George Hripcsak; Linnea Capps; David Liss
Journal:  J Am Med Inform Assoc       Date:  2002 Jan-Feb       Impact factor: 4.497

2.  Diabetic Retinopathy Analysis.

Authors:  R Sivakumar; G Ravindran; M Muthayya; S Lakshminarayanan; C U Velmurughendran
Journal:  J Biomed Biotechnol       Date:  2005

3.  Haptoglobin2-2 phenotype is an additional risk factor of retinopathy in type 2 diabetes mellitus.

Authors:  Mukund R Mogarekar; Mahesh H Hampe
Journal:  Indian J Hum Genet       Date:  2013-04

4.  Genetics in diabetic retinopathy: current concepts and new insights.

Authors:  Olga Simó-Servat; Cristina Hernández; Rafael Simó
Journal:  Curr Genomics       Date:  2013-08       Impact factor: 2.236

Review 5.  Circulating Biomarkers of Diabetic Retinopathy: An Overview Based on Physiopathology.

Authors:  Olga Simó-Servat; Rafael Simó; Cristina Hernández
Journal:  J Diabetes Res       Date:  2016-06-08       Impact factor: 4.011

6.  Diabetic Retinopathy in Patients with Diabetic Nephropathy: Development and Progression.

Authors:  Chi-Juei Jeng; Yi-Ting Hsieh; Chung-May Yang; Chang-Hao Yang; Cheng-Li Lin; I-Jong Wang
Journal:  PLoS One       Date:  2016-08-26       Impact factor: 3.240

7.  Analysis of factors related to diabetic retinopathy in patients with newly diagnosed type 2 diabetes: a cross-sectional study.

Authors:  Zhaohu Hao; Xiao Huang; Yongzhang Qin; Huanming Li; Fengshi Tian; Rong Xu; Baocheng Chang; Hailin Shao
Journal:  BMJ Open       Date:  2020-02-10       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.